Moore Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Moore Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,800	Closed	-$13.5M	–	542
2024 Q2	$13.5M	Sell	12,800 -4,200	-25%	-$4.07M	0.23%	113
2024 Q1	$16.4M	Buy	17,000 +6,000	+55%	+$5.71M	0.26%	89
2023 Q4	$9.66M	Buy	+11,000	New	+$9.06M	0.17%	97
2023 Q2	–	Sell	-10,000	Closed	-$8.22M	–	579
2023 Q1	$8.22M	Buy	+10,000	New	+$7.54M	0.17%	109
2022 Q4	–	Sell	-41,991	Closed	-$28.9M	–	625
2022 Q3	$28.9M	Buy	41,991 +18,264	+77%	+$11.5M	0.68%	27
2022 Q2	$14M	Buy	23,727 +6,521	+38%	+$4.24M	0.37%	51
2022 Q1	$12M	Buy	+17,206	New	+$10.9M	0.31%	62
2021 Q3	–	Sell	-42,640	Closed	-$23.8M	–	858
2021 Q2	$23.8M	Buy	+42,640	New	+$21.6M	0.34%	65
2021 Q1	–	Sell	-22,804	Closed	-$11M	–	762
2020 Q4	$11M	Buy	+22,804	New	+$12.3M	0.12%	123

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Moore Capital Management's REGN Position: Q3 2024 in Review

Moore Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2024, closing a stake of 12,800 shares — an estimated $13.5M sold.

Moore Capital Management first reported a position in REGN in Q4 2020 and held it in 9 quarters. The position peaked at $28.9M in Q3 2022. 1,391 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

Moore Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Moore Capital Management sold 12,800 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $13.5M.
Moore Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 9 quarters.
Moore Capital Management's Regeneron Pharmaceuticals position peaked at $28.9M in Q3 2022.
1,391 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on Moore Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.